GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: TransCon CNP
Compound class:
Peptide
Comment: Navepegritide (TransCon CNP) is a prodrug of a human C-type natriuretic peptide (CNP) analogue [1]. It comprises CNP(1-38) attached to an inert polyethylene glycol carrier via a cleavable linker [3]. CNP is a validated therapeutic agent for the treatment of patients with achondroplasia (see the approved CNP analogue vosoritide) [2]. Navepegritide is designed to provide sustained hormone release and continuous CNP exposure as a once-weekly therapy that is proposed to counterbalance the overactivated FGFR3 signaling pathway in achondroplasia [1].
|
| Bioactivity Comments |
| Agonist activity at the natriuretic peptide receptor-B (guanylyl cyclase B; NPR2) is expected to be similar to that of endogenous CNP-38 [1]. |
| Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
